Search | IOVS | ARVO Journals

Showing 1 – 20 of 72

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract June 2020

Complications, Compliance and 2 Year Outcomes after Endolaserless Vitrectomy with Aflibercept Monotherapy for PDR-Related Vitreous Hemorrhage

Rachel Levy; Davis Clark Starnes; Harveen Walia; Amina Farooq; Heather Frazier; William Marcus; Evin Samy; Caitlen Taylor; Robert Lalane; Harinderjit Singh; Dennis M Marcus

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):1380. doi:

ARVO Annual Meeting Abstract June 2020

Patient Characteristics Affecting Incidence of Vision-Threatening Events (VTC) and Center-Involved Diabetic Macular Edema (DME) in Moderately Severe-to-Severe Nonproliferative Diabetic Retinopathy (NPDR)

Dennis M Marcus

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):295. doi:

ARVO Annual Meeting Abstract July 2019

Endolaserless Vitrectomy with Intravitreal Aflibercept Injection (IAI) for Proliferative Diabetic Retinopathy (PDR)-Related Vitreous Hemorrhage: LASER LESS TRIAL 1-Year Results

Davis Clark Starnes; Robert Lalane; Harveen Walia; Amina Farooq; Heather Frazier; William Marcus; Harinderjit Singh; Dennis M Marcus

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):6559. doi:

ARVO Annual Meeting Abstract July 2019

Wide-Field Fluorescein Angiographic-Guided Aflibercept (WFFAGA) Monotherapy for Proliferative Diabetic Retinopathy (PDR)

Lindsay Williamson; Davis Starnes; Caitlen Taylor; Rachel Levy; Venkatkrish Kasetty; Priscila Rex; Harinderjit Singh; Robert Lalane; Dennis M Marcus

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):5334. doi:

ARVO Annual Meeting Abstract July 2019

The Effect of Sleep Disorders on Retinal Peripapillary, Macular, and Optic Nerve Anatomy

Arash Davanian; Lindsay Williamson; Kathryn E Bollinger; Bashir Chaudhary; Dennis M Marcus

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):6149. doi:

ARVO Annual Meeting Abstract July 2019

Intravitreal Aflibercept Injection (IAI) for Persistent Diabetic Macular Edema (DME) after Treatment with Bevacizumab and/or Ranibizumab: ROTATED Trial 52 Week Results

Caitlen Taylor; Heather Frazier; Priscila Rex; William Marcus; Davis Starnes; Harveen Walia; Harinderjit Singh; Robert Lalane; Dennis M Marcus

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):3642. doi:

ARVO Annual Meeting Abstract July 2018

Intravitreal Aflibercept Injection (IAI) for Persistent Diabetic Macular Edema (DME) after Treatment with Bevacizumab and/or Ranibizumab: 6-Month ROTATED Trial Results

Dennis M Marcus; Heather Frazier; Priscila Rex; William Marcus; Davis Starnes; Harveen Walia; Harinderjit Singh; Robert Lalane

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):3598. doi:

ARVO Annual Meeting Abstract June 2017

Endolaserless Vitrectomy with Intravitreal Aflibercept Injection (IAI) for Proliferative Diabetic Retinopathy (PDR)-Related Vitreous Hemorrhage (LASER LESS TRIAL)

Dennis M Marcus; Harinderjit Singh; Amina Farooq; Davis Starnes; Harveen Walia

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):5036. doi:

ARVO Annual Meeting Abstract September 2016

Ranibizumab (0.3 MG) For Persistent Diabetic Macular Edema (DME) After Recent, Frequent, And Chronic Bevacizumab: 1-Year Rotate Trial Results

Amina Farooq; Heather Frazier; Chelsea Fechter; William Baker Marcus; Harinderjit Singh; Dennis M Marcus

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):2093. doi:

ARVO Annual Meeting Abstract September 2016

Intravitreal Aflibercept For Neovascular Polypoidal Choroidal Vasculopathy In A Predominantly Non-Asian Population: 1-Year Rival Trial Results

Dennis M Marcus; Amina Farooq; Heather Frazier; Chelsea Fechter; William Baker Marcus; Harinderjit Singh

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):535. doi:

ARVO Annual Meeting Abstract June 2015

Evaluation of Rescue Treatment with Intravitreal Aflibercept Injection (IAI) in Patients with Diabetic Macular Edema (DME) Randomized to Laser in the VISTA and VIVID Studies

Dennis M Marcus; VISTA and VIVID study investigators

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):1763. doi:

ARVO Annual Meeting Abstract June 2015

High-Dose Ranibizumab for Non-Asian Neovascular Polypoidal Choroidal Vasculopathy

Chelsea Fechter; Dennis M Marcus; Harinderjit Singh; Drew Chamberlain

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):5385. doi:

ARVO Annual Meeting Abstract April 2014

Intravitreal Aflibercept for the treatment of Choroidal Neovascularization (CNV) secondary to Presumed Ocular Histoplasmosis Syndrome (POHS): Short-term Results From the HANDLE Study

Brian Toussaint; Dennis M Marcus; Daniel Miller; John W Kitchens; Harinderjit Singh; Robert Foster; Michael R Petersen; Robert Sisk; Christopher Riemann

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):3923. doi:

ARVO Annual Meeting Abstract April 2014

Long-term Follow-up of Intravitreal Aflibercept Injection (IAI) for Neovascular Age-Related Macular Degeneration (nAMD) in an Open-Label Extension of the VIEW1 Study

Dennis M Marcus; View Extension Study Group

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):3943. doi:

ARVO Annual Meeting Abstract June 2013

Amyloid Beta 1- 42 Promotes NLRP3-inflammasome Activation In Retinal Pigmented Epithelial Cells

Matthew West; Folami Lamoke; AnnaLisa Montemari; Giovanni Parisi; Guido Ripandelli; Dennis Marcus; Manuela Bartoli

Invest. Ophthalmol. Vis. Sci.. 2013; 54(15):4994. doi:

ARVO Annual Meeting Abstract March 2012

A Microfabricated, Combination Flexible Circuit/Electrode Array for a Subretinal Prosthesis

Marcus D. Gingerich; Roman Akhmechet; Stuart F. Cogan; Timothy D. Plante; Douglas B. Shire; John L. Wyatt, Jr.; Joseph F. Rizzo, III

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):5515. doi:

ARVO Annual Meeting Abstract March 2012

A Microfabricated Chronic Percutaneous Penetrating Electrode Array for a Subretinal Prosthesis

Bruce W. McKee; Marcus D. Gingerich; Stuart F. Cogan; Douglas B. Shire; John L. Wyatt; Joseph F. Rizzo, III

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):5545. doi:

ARVO Annual Meeting Abstract March 2012

Overview of Progress on the 256+ Channel Boston Retinal Prosthesis

Joseph F. Rizzo, III; Jinghua Chen; Douglas B. Shire; Shawn K. Kelly; William D. Eldred; William K. Jones; Patrick Doyle; Marcus D. Gingerich; John L. Wyatt

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):1313. doi:

Retinal Cell Biology August 2011

Hyperoxia Therapy of Pre-Proliferative Ischemic Retinopathy in a Mouse Model

PDF

Wenbo Zhang; Harumasa Yokota; Zhimin Xu; Subhadra P. Narayanan; Lauren Yancey; Akitoshi Yoshida; Dennis M. Marcus; Robert W. Caldwell; Ruth B. Caldwell; Steven E. Brooks
TAGS: hyperoxia, ischemia, mice, retina, retinal diseases, vascular endothelial growth factor a, oxygen, revascularization
Invest. Ophthalmol. Vis. Sci.. 2011; 52(9):6384-6395. doi: https://doi.org/10.1167/iovs.11-7666

Includes: Supplemental Content

ARVO Annual Meeting Abstract April 2011

Epigenetic Regulation of Endogenous Antioxidants in the Diabetic Retina

Folami Lamoke; Chaunte Stampley; Annamaria Maraschi; Frances Fan; Annalisa Montemari; Dennis M. Marcus; Pamela M. Martin; Manuela Bartoli

Invest. Ophthalmol. Vis. Sci.. 2011; 52(14):4448. doi:

1 2 3 4

Next 20 Results »

NARROW

Content Type

Journal

Article Type

Topics

Tags

Specify Date Range

Complications, Compliance and 2 Year Outcomes after Endolaserless Vitrectomy with Aflibercept Monotherapy for PDR-Related Vitreous Hemorrhage

Patient Characteristics Affecting Incidence of Vision-Threatening Events (VTC) and Center-Involved Diabetic Macular Edema (DME) in Moderately Severe-to-Severe Nonproliferative Diabetic Retinopathy (NPDR)

Endolaserless Vitrectomy with Intravitreal Aflibercept Injection (IAI) for Proliferative Diabetic Retinopathy (PDR)-Related Vitreous Hemorrhage: LASER LESS TRIAL 1-Year Results

Wide-Field Fluorescein Angiographic-Guided Aflibercept (WFFAGA) Monotherapy for Proliferative Diabetic Retinopathy (PDR)

The Effect of Sleep Disorders on Retinal Peripapillary, Macular, and Optic Nerve Anatomy

Intravitreal Aflibercept Injection (IAI) for Persistent Diabetic Macular Edema (DME) after Treatment with Bevacizumab and/or Ranibizumab: ROTATED Trial 52 Week Results

Intravitreal Aflibercept Injection (IAI) for Persistent Diabetic Macular Edema (DME) after Treatment with Bevacizumab and/or Ranibizumab: 6-Month ROTATED Trial Results

Endolaserless Vitrectomy with Intravitreal Aflibercept Injection (IAI) for Proliferative Diabetic Retinopathy (PDR)-Related Vitreous Hemorrhage (LASER LESS TRIAL)

Ranibizumab (0.3 MG) For Persistent Diabetic Macular Edema (DME) After Recent, Frequent, And Chronic Bevacizumab: 1-Year Rotate Trial Results

Intravitreal Aflibercept For Neovascular Polypoidal Choroidal Vasculopathy In A Predominantly Non-Asian Population: 1-Year Rival Trial Results

Evaluation of Rescue Treatment with Intravitreal Aflibercept Injection (IAI) in Patients with Diabetic Macular Edema (DME) Randomized to Laser in the VISTA and VIVID Studies

High-Dose Ranibizumab for Non-Asian Neovascular Polypoidal Choroidal Vasculopathy

Intravitreal Aflibercept for the treatment of Choroidal Neovascularization (CNV) secondary to Presumed Ocular Histoplasmosis Syndrome (POHS): Short-term Results From the HANDLE Study

Long-term Follow-up of Intravitreal Aflibercept Injection (IAI) for Neovascular Age-Related Macular Degeneration (nAMD) in an Open-Label Extension of the VIEW1 Study

Amyloid Beta 1- 42 Promotes NLRP3-inflammasome Activation In Retinal Pigmented Epithelial Cells

A Microfabricated, Combination Flexible Circuit/Electrode Array for a Subretinal Prosthesis

A Microfabricated Chronic Percutaneous Penetrating Electrode Array for a Subretinal Prosthesis

Overview of Progress on the 256+ Channel Boston Retinal Prosthesis

Hyperoxia Therapy of Pre-Proliferative Ischemic Retinopathy in a Mouse Model

Epigenetic Regulation of Endogenous Antioxidants in the Diabetic Retina

To View More...

You must be signed into an individual account to use this feature.